Medical Doctor Program year 2023 Reported 2022–2023 Source: CMS Open Payments, 2026 publication

Kristen Zeller-Hack

Pain Medicine St Louis Park, MN Medical Doctor

NPI 1316982382 CMS profile 59432

3800 Park Nicollet Blvd, St Louis Park, MN 55416

Open in the dashboard

General payments

$165

2 records reported · program years 2022–2023

Research payments

$0

Paid to them · None reported · program years 2022–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kristen Zeller-Hack of St Louis Park, MN is reported in the CMS Open Payments database as having received $165 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 15th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $105 1
2022 General $60 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Zeller-Hack
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kristen Zeller-Hack were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Kristen Zeller-Hack Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $60 $455 $137–$1,484 $149
2023 $105 $484 $128–$1,495 $160
2024 $0 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2022–2023
  1. Boston Scientific Corporation $165 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2023
  1. Food and Beverage $165 2 payments
Products named General payments · program years 2022–2023
  1. WaveWriter Alpha Prime 16 $165 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

907

Median for Interventional Pain Management: 1,220

Drug cost

$21,419

Median for Interventional Pain Management: $39,344

Branded share of claims

41.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 11 $5,224
Gabapentin Generic 135 $3,187
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 137 $3,079
Morphine Sulfate Er Morphine Sulfate Brand 100 $2,938
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 132 $1,784
Oxycodone Hcl Generic 70 $1,256
Pregabalin Generic 45 $960
Baclofen Generic 33 $835
Tramadol Hcl Generic 98 $757
Tizanidine Hcl Generic 37 $589

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$85,307

Of which drugs: $952

Medicare patients

229

Average age 72

Services billed

4,913

148 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 35%
Diabetes 24%
Osteoporosis 22%
Chronic kidney disease 18%
Ischemic heart disease 16%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 48 359 $273
Injection, methylprednisolone acetate, 1 mg J1010 Office 25 1,991 $204
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 168 690 $191
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 72 777 $66
Injection, fentanyl citrate, 0.1 mg J3010 Office 15 20 $15
Injection, midazolam hydrochloride, per 1 mg J2250 Office 16 42 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record